|
Researchers from the UTRGV School of Medicine and MD Anderson Cancer Center have identified MUC13 as a promising biomarker and therapeutic target for metastatic colorectal cancer, opening the door to more precise cancer imaging and treatment strategies.
The study, published in Clinical Cancer Research, was led by Dr. Subhash Chauhan, director of the South Texas Center of Excellence in Cancer Research, in collaboration with Dr. H. Charles Manning and colleagues at MD Anderson.
Researchers found that MUC13 is highly expressed in many metastatic colorectal cancers, making it a potential target for next-generation radiopharmaceutical therapies designed to destroy cancer cells while minimizing damage to healthy tissue selectively.
The findings represent an important step toward developing more targeted treatment options for patients with advanced colorectal cancer and lay the groundwork for future clinical studies.
|